Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.
about
Inducible Nitric Oxide Inhibitors Block NMDA Antagonist-Stimulated Motoric Behaviors and Medial Prefrontal Cortical Glutamate Efflux.Inflammatory biomarkers as differential predictors of antidepressant responseNegative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple DomainsExperimental medication treatment approaches for depression.New targets for rapid antidepressant action.Clinical applications of hallucinogens: A review.Beyond serotonin: newer antidepressants in the future.GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.New Hippocampal Neurons Mature Rapidly in Response to Ketamine But Are Not Required for Its Acute Antidepressant Effects on Neophagia in Rats.Duality of Antidepressants and Neuroprotectants.Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studiesCurrent Trends in Identifying Rapidly Acting Treatments for DepressionTranslational psychiatry--light at the end of the tunnel.New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors.Ketamine-dependent neuronal activation in healthy volunteers.Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling.Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.Cortical thickness reduction in combat exposed U.S. veterans with and without PTSD.Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization.Ketamine induced converged synchronous gamma oscillations in the cortico-basal ganglia network of nonhuman primates.Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies.Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway.Microglia Loss Contributes to the Development of Major Depression Induced by Different Types of Chronic Stresses.Decreased levels of kynurenic acid in prefrontal cortex in a genetic animal model of depression.Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression.Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.Comparative Transcriptomic Analysis of the Effects of Antidepressant Drugs in Stress-Susceptible Mice.Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed PatientsPrefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine TreatmentKetamine’s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical StudiesEffect of low-dose ketamine on PerioperAtive depreSsive Symptoms in patients undergoing Intracranial tumOr resectioN (PASSION): study protocol for a randomized controlled trial
P2860
Q27308077-BAB5C764-5C91-4994-A7AA-6C46FF395659Q28081799-DD62298C-3504-46FF-9859-C2597A5FDF73Q30830257-2D26040D-A45D-4F9E-9AF7-3D11E0124466Q33635577-5236C75E-EA76-4159-9F1D-56568228EF9DQ34507177-65487DF3-9F85-4DC0-8DB9-527010CAD348Q34535259-517587F2-584A-48CE-80EE-5BCF22838603Q34557706-2A72042F-3147-4F82-B987-63430ED5D16CQ36486035-2DB50FBF-1626-4E1F-BA9C-A085E62435A6Q36760914-B12D9484-FC00-49D0-BB13-5E3D323AB050Q36944840-84166233-66E2-4ED9-9D31-7724C53F5E08Q37114639-044325B6-793B-42AF-8804-B22887EB3A4FQ37210886-0D975335-7486-40CC-9A7F-41B3A57861CAQ38370696-C4C6C54B-4451-46A6-AC1D-76DAD2F8EB9AQ38685420-D6325F51-4A3A-4F4A-9DAC-0434555C3610Q38787388-636D7FEB-8F9F-4CC2-9F9F-5F29D19C1FB5Q38793772-574F2C7B-8A65-4109-A991-0D80D29863B3Q38803371-6FA7E800-6CDC-4DD9-A815-5EC3815149F2Q38803429-2C2C7FF8-8238-4361-BCF3-C3411E80A359Q38934855-2C1F43C9-BBCD-49EB-A0F2-C422DB25C4E4Q39437669-8AFA1C37-218C-471E-88A3-642DDFEF0BACQ41659149-C4A9F6C2-ED61-4F75-AB1C-95C9838D028FQ41729281-B0F564DF-A7A6-41C7-9D4E-CBE606F99439Q45326808-DBE0BC6E-6B7F-427C-915B-55ADE5941838Q47255869-F18462C3-9732-4725-98A0-77B07EF53572Q47300330-F80D1D8F-AB70-45A5-BC23-FC3A84E13ECCQ47383203-B44096F9-1E45-4558-8269-4BE57202066AQ47616820-635595BF-B5BC-4CD1-A2E2-9676551D071CQ47901145-71B84B9F-F589-449A-A6BC-5DE8C3E7E21BQ48049046-F0926108-7058-4D09-9007-E8354B50F85EQ48067247-31FC148C-9E89-4ADA-A71C-AAA02803F20EQ49712840-8D7F1FA0-0022-470A-9683-809571144D0BQ55078223-C12CB748-37AF-4734-9362-468380707248Q58213311-1B287112-A3AF-4412-A01B-713EFE1BA2F5Q58213868-19C2FE35-84DD-4878-B64C-73D509700DA8Q58213893-49BEE309-5932-4272-A45A-90E641E7E990Q58696620-CD6C70D0-93DC-44D5-A757-6BAB7936331A
P2860
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.
@ast
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.
@en
type
label
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.
@ast
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.
@en
prefLabel
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.
@ast
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.
@en
P2860
P356
P1476
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.
@en
P2093
John H Krystal
P2860
P356
10.1111/NYAS.12718
P407
P577
2015-02-27T00:00:00Z